Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

Subscribe To Our Latest Investor News

News Highlights
April 10, 2021

Combination of copanlisib and rituximab significantly increases progression-free survival in patients with relapsed indolent non-Hodgkin's Lymphoma

READ MORE
April 6, 2021

Bayer to present new clinical data at AACR Annual Meeting 2021

READ MORE
March 23, 2021
Not intended for U.S. and UK Media

Bayer receives approval for Vitrakvi™ in Japan

READ MORE
March 12, 2021

Elections at the Annual Stockholders' Meeting on April 27, 2021

Read more
AD HOC

Discover Bayer’s Latest Ad Hoc Releases

READ MORE
Explore All
61 - 70of about 613 News
61 - 70of about 613 News
June 15, 2020
Not intended for U.S. and UK Media
Bayer extends clinical development program for finerenone with Phase III study in patients with heart failure and preserved ejection fraction
READ MORE
June 05, 2020
Not intended for U.S. and UK Media
Bayer submits vericiguat for marketing authorization in the EU and Japan for the treatment of chronic heart failure
READ MORE
May 29, 2020
Not intended for U.S. and UK Media - American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program):
Efficacy of Vitrakvi™ (larotrectinib) further established with continued high response rates and durable response in updated analyses in adult patients and quality of life data in adult and pediatric patients with TRK fusion cancer
READ MORE
May 22, 2020
Not intended for U.S. and UK Media
Bayer submits larotrectinib for marketing authorization in Japan for the treatment of TRK fusion cancer
READ MORE
May 19, 2020
Nine internationally recognized experts join Sustainability Council
Independent external council to advise Bayer’s Board of Management on consistent implementation of its sustainability targets
READ MORE
May 13, 2020
Not intended for U.S. and UK Media - New ARAMIS Phase III data to be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
Nubeqa™ (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancer
READ MORE
May 11, 2020
Not intended for U.S. and UK Media
Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program
READ MORE
April 28, 2020
CEO Werner Baumann at the Bayer AG Annual Stockholders’ Meeting:
“We’re active in the right businesses”
READ MORE
April 27, 2020
First quarter of 2020:
Bayer: Good start to 2020 – activities marked by COVID-19
READ MORE
April 21, 2020
Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments
READ MORE
61 - 70of about 613 News
61 - 70of about 613 News